medical devices and IVD clinical expertise will increase because of the acquisition of Devicia and Clarvin by Veranex
Veranex, the only comprehensive, international, technology-enabled service provider to the medical device industry, announced today that it has acquired a network of full-service medical device consulting companies that cover clinical and regulatory activities, quality assurance, and offer biocompatibility services for medical devices and in vitro diagnostic (IVD) devices. This environment is based in Sweden and includes Kickfile, Lea Reg, and Limulus Bio as well as Clarvin, a provider of strategic regulatory and quality assurance consultancy services, and Devicia, a full-service partner with clinical competence. These companies broaden Veranex’s presence in Europe and result in an expansion of the regulatory, clinical, and quality service divisions in the context of the newly acquired Medidee, a Swiss company.
This strengthens Veranex’s strategy in the areas of Medical Device Regulations (MDR) and In Vitro Diagnostics in particular, as well as the company’s infrastructure and local representations in the European Union and the United Kingdom. It also results in the accumulation of knowledge in biological evaluation and medical technology software.
” This group of companies, led by Devicia and Clarvin, shares the same goal as Veranex: to work with our customers to create and accelerate innovation in medtech”, ” Devicia, Clarvin and their subsidiaries focus exclusively on medical devices and IVD, providing strategic advice and informed execution across multiple areas, including clinical testing, medical writing, regulatory strategies, toxicological assessment, designated local agents and systems technologies that provide the full service.” Veranex capabilities and solutions in the MedTech space.”
David Dockhorn, CEO of Veranex
Veranex’s global reach is widened by the group of firms, which adds three new facilities in the US and Europe.
“ We are very pleased about the opportunity to support our customers even more extensively with our comprehensive medical device and IVD services and to show a significantly strengthened global presence. We believe that a global perspective and wide geographic reach add strategic value to our clients’ market access,”
Elisabeth Liljensten, CEO of Devicia
” From the first interaction with Veranex, it was clear to us that we share the same vision for optimal customer support — with a combination of regulatory intelligence, expertise in different areas and a truly global presence.”
Asa Runnas, CEO of Clarvin
In this deal, Veranex received financial and legal advice from Alvarez & Marsal (A&M) and McDermott Will & Emery (MWE), respectively. Kanter served as the group Devicia and Clarvin’s legal counsel, and Christopher Fägerskiöld AB served as its finance advisor. Its financial information is not disclosed.
For More Healthcare News Click Here
